Poseida Therapeutics, Inc. (PSTX)
After hours:
| Previous close | 2.6700 |
| Open | 2.6300 |
| Bid | 2.3900 x 1300 |
| Ask | 2.6600 x 1100 |
| Day's range | 2.3819 - 2.6500 |
| 52-week range | 1.5400 - 8.8200 |
| Volume | |
| Avg. volume | 489,803 |
| Market cap | 252.448M |
| Beta (5Y monthly) | -0.01 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced updates and financial results for the third quarter ended September 30, 2023.
- PR Newswire
Poseida Therapeutics to Present at Two Upcoming Investor Conferences
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced that the Company will participate in the following upcoming investor conferences in November:
- PR Newswire
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
Poseida Therapeutics, Inc. (Nasdaq: PSTX), a clinical-stage cell and gene therapy company advancing a new class of treatments for patients with cancer and rare diseases, today announced the acceptance of three poster presentations at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition being held at the San Diego Convention Center in San Diego and virtually on December 9-12, 2023.
